ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN update- 2020 in review

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Dec 14, 2020 3:59pm

89 Views

Post# 32102166

RE:RE:RE:PMN update- 2020 in review

I don't doubt that this certainly caused issues, but based on the Alzforum autopsy comments and BAN2401 results, it seems like the amyloid beta hypothesis is good to go.

I am still optimistic about a deal given the market opportunity and the cash piling up out there in big pharma. Sounds like it will take some time though.

I am still suspicious that we are waiting on Biogen for some reason... Perhaps for a good reason

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles